Anifrolumab in the Real-World Management of Systemic Lupus Erythematosus
Real-world data show about one-quarter of lupus patients achieve six-month remission with anifrolumab, supporting earlier targeted therapy, steroid reduction, and evolving care pathways for systemic lupus erythematosus.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.